Vermillion Sets Third Quarter 2013 Conference Call for Thursday, November 14, 2013

Vermillion Sets Third Quarter 2013 Conference Call for Thursday, November 14,
                                     2013

PR Newswire

AUSTIN, Texas, Oct. 31, 2013

AUSTIN, Texas, Oct. 31, 2013 /PRNewswire/ --Vermillion, Inc. (NASDAQ: VRML),
a multivariate diagnostics company focused on gynecologic cancers and women's
health, will hold a conference call on Thursday, November 14, 2013, at 4:30
p.m. Eastern time to discuss results for the third quarter ended September 30,
2013. Financial results will be issued in a press release prior to the call.

Vermillion's President and CEO Thomas McLain will host the call, followed by a
question and answer period.

Date: Thursday, November 14, 2013
Time: 4:30 p.m. Eastern time (3:30 p.m. Central time)
Dial-in number: 1-800-734-8507
International dial-in number: 1-212- 231-2918
Conference ID: 21676489
Webcast: http://www.media-server.com/m/p/kb996t2n

The conference call will be webcast live and available for replay via the
investor section of the company's website at www.vermillion.com.

Please call the conference telephone number 5-10 minutes prior to the start
time. An operator will register your name and organization. If you have any
difficulty connecting with the conference call, please contact Liolios Group
at 1-949-574-3860.

A replay of the call will be available approximately two hours after the call
through November 28, 2013.

Toll-free replay number: 1-800-633-8284
International replay number: 1-402-977-9140
Replay ID: 21676489

About Vermillion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and
commercialization of novel high-value diagnostic tests that help physicians
diagnose, treat and improve outcomes for patients. Vermillion, along with its
prestigious scientific collaborators, has diagnostic programs in gynecologic
oncology and women's health.

The company's lead diagnostic, OVA1®, is a blood test for pre-surgical
assessment of ovarian tumors for malignancy, using an innovative algorithmic
approach. As the first FDA-cleared, protein-based In Vitro Diagnostic
Multivariate Index Assay, OVA1 represents a new class of software-based
diagnostics. For additional information, including published clinical trials,
visit www.vermillion.com.

Investor Relations Contact:
Liolios Group, Inc.
Ron Both
Tel 1-949-574-3860
vrml@liolios.com

SOURCE Vermillion, Inc.

Website: http://www.vermillion.com
 
Press spacebar to pause and continue. Press esc to stop.